Last reviewed · How we verify

GSK2585823(CLDM 1%-BPO 3% gel)

GlaxoSmithKline · Phase 3 active Small molecule

GSK2585823(CLDM 1%-BPO 3% gel) is a Topical antibiotic combination Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Acne vulgaris. Also known as: GSK2585823.

This combination gel delivers clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial and keratolytic agent) topically to reduce acne-causing bacteria and inflammation.

This combination gel delivers clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial and keratolytic agent) topically to reduce acne-causing bacteria and inflammation. Used for Acne vulgaris.

At a glance

Generic nameGSK2585823(CLDM 1%-BPO 3% gel)
Also known asGSK2585823
SponsorGlaxoSmithKline
Drug classTopical antibiotic combination
TargetBacterial protein synthesis (clindamycin); oxidative antimicrobial activity (benzoyl peroxide)
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis, effective against Cutibacterium acnes. Benzoyl peroxide acts as an oxidizing agent that kills bacteria and helps shed dead skin cells. The combination targets both bacterial and inflammatory components of acne pathogenesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GSK2585823(CLDM 1%-BPO 3% gel)

What is GSK2585823(CLDM 1%-BPO 3% gel)?

GSK2585823(CLDM 1%-BPO 3% gel) is a Topical antibiotic combination drug developed by GlaxoSmithKline, indicated for Acne vulgaris.

How does GSK2585823(CLDM 1%-BPO 3% gel) work?

This combination gel delivers clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial and keratolytic agent) topically to reduce acne-causing bacteria and inflammation.

What is GSK2585823(CLDM 1%-BPO 3% gel) used for?

GSK2585823(CLDM 1%-BPO 3% gel) is indicated for Acne vulgaris.

Who makes GSK2585823(CLDM 1%-BPO 3% gel)?

GSK2585823(CLDM 1%-BPO 3% gel) is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is GSK2585823(CLDM 1%-BPO 3% gel) also known as anything else?

GSK2585823(CLDM 1%-BPO 3% gel) is also known as GSK2585823.

What drug class is GSK2585823(CLDM 1%-BPO 3% gel) in?

GSK2585823(CLDM 1%-BPO 3% gel) belongs to the Topical antibiotic combination class. See all Topical antibiotic combination drugs at /class/topical-antibiotic-combination.

What development phase is GSK2585823(CLDM 1%-BPO 3% gel) in?

GSK2585823(CLDM 1%-BPO 3% gel) is in Phase 3.

What are the side effects of GSK2585823(CLDM 1%-BPO 3% gel)?

Common side effects of GSK2585823(CLDM 1%-BPO 3% gel) include Skin irritation, Erythema, Dryness, Peeling.

What does GSK2585823(CLDM 1%-BPO 3% gel) target?

GSK2585823(CLDM 1%-BPO 3% gel) targets Bacterial protein synthesis (clindamycin); oxidative antimicrobial activity (benzoyl peroxide) and is a Topical antibiotic combination.

Related